GlassScriptPhysician profile
Rodney Rencher
NPI 1497354922
$1,448.82
in general payments reported to CMS, 2019-2025
29 companies · $85.98 in 2025
The $85.98 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $233 · 2023: $414 · 2024: $256 · 2025: $85.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $299.50 | 2021-2023 | |
| Lilly USA, LLC | $121.69 | 2021-2025 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $105.23 | 2021-2025 | Airsupra, Farxiga |
| Lundbeck LLC | $93.56 | 2022-2024 | Rexulti |
| Pfizer INC. | $85.61 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.23 | 2023-2024 | Caplyta |
| Alkermes, INC. | $65.99 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Jazz Pharmaceuticals INC. | $65.95 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.47 | 2021-2023 | Trintellix |
| Noven Therapeutics, LLC | $49.38 | 2023 | Xelstrym, Secuado |
| Otsuka America Pharmaceutical, INC. | $39.07 | 2022-2023 | Rexulti |
| Tris Pharma INC | $38.31 | 2022 | |
| Novo Nordisk INC | $36.69 | 2021-2022 | |
| Genentech USA, INC. | $36.41 | 2021 | |
| Corium, LLC | $31.54 | 2023 | Azstarys |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.82 | 2021-2025 | Spravato |
| Adlon Therapeutics L.P. | $27.22 | 2021 | |
| Sunovion Pharmaceuticals INC. | $26.97 | 2021 | |
| Amarin Pharma, INC. | $19.93 | 2021 | |
| Ibsa Pharma INC. | $16.52 | 2021 | |
| Eisai INC. | $16.49 | 2021 | |
| Axsome Therapeutics, INC. | $16.43 | 2023 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $15.04 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.69 | 2022 | |
| Almatica Pharma LLC | $13.62 | 2024 | Loreev Xr |
| Neos Therapeutics, LP | $13.59 | 2021 | |
| Medtronic, INC. | $13.50 | 2024 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $12.95 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Rencher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.